Nearly three decades later, drug makers have developed six approved small interfering RNA (siRNA) therapeutics in the ...

Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

The firm has made significant strides in its RNA editing and RNA interference programs, which are attracting positive attention and positioning the company for differentiation in the treatment of ...

Compared to DNA sequencing alone, concurrent DNA and RNA sequencing revealed more clinically actionable variants in NSCLC.

Avidity Biosciences stock surges on expansion of pipeline targeting rare genetic cardiomyopathies and improvements in siRNA ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

Most people don’t enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such ...

Our best-in-class RNA platform is consistently translating in the clinic and demonstrating how we can uniquely design, and ...

A groundbreaking study introduces stable inhalable mRNA treatment using nanoparticles that hold up during nebulization, ...

Phlox Therapeutics is developing Ribonucleic acid (RNA)-based gene therapies to treat cardiomyopathies, disorders that affect the heart muscle.

The company describes the precision medicine test as the first of its kind to offer simultaneous whole exome sequencing and ...

TD Cowen analyst Ritu Baral maintained a Buy rating on Avidity Biosciences (RNA – Research Report) today and set a price target of $78.00. The company’s shares closed yesterday at $46.73. Baral covers ...